United Therapeutics
UTHR
320 hedge funds and large institutions have $3.27B invested in United Therapeutics in 2019 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 94 increasing their positions, 131 reducing their positions, and 105 closing their positions.
2.31% less ownership
Funds ownership: 98.02% → 95.71% (-2.3%)
15% less funds holding
Funds holding: 378 → 320 (-58)
21% less call options, than puts
Call options by funds: $27.3M | Put options by funds: $34.7M
28% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 131
35% less capital invested
Capital invested by funds: $5.01B → $3.27B (-$1.74B)
49% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 105
57% less funds holding in top 10
Funds holding in top 10: 7 → 3 (-4)
Top Buyers
| 1 |
Millennium Management
New York
|
+$154M |
| 2 |
Renaissance Technologies
New York
|
+$74.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$63.9M |
| 4 |
Two Sigma Investments
New York
|
+$54.4M |
| 5 |
D.E. Shaw & Co
New York
|
+$52.2M |
Top Sellers
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$127M |
| 2 |
APG Asset Management
Amsterdam,
Netherlands
|
-$66.4M |
| 3 |
BlackRock
New York
|
-$47M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$44.6M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$42.5M |
UTHR Hedge Fund Activity: Q2 2019 in Review
320 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2019, worth a combined $3.27B — down 35% from $5.01B a quarter earlier.
Sellers outnumbered buyers: 105 funds closed out of UTHR and 54 opened new positions — a net loss of 51 holders — while 131 trimmed existing stakes and 94 added.
The largest buyer was Millennium Management, adding an estimated $154M. The largest seller was AQR Capital Management, cutting an estimated $127M.
- 320 institutional investors held United Therapeutics (UTHR) as of Q2 2019, down from 378 in Q1 2019.
- Funds reported $3.27B of United Therapeutics stock for Q2 2019, down 35% quarter-over-quarter.
- 54 funds opened new United Therapeutics positions in Q2 2019 and 105 closed out, a net change of -51 holders.
- The largest United Therapeutics buyer in Q2 2019 was Millennium Management, an estimated $154M added.
- The largest United Therapeutics seller in Q2 2019 was AQR Capital Management, an estimated $127M sold.
Based on aggregated 13F filings for Q2 2019.